Episode 186: Helping Women On Chemotherapy: An Entrepreneur Journey

Episode 186: Helping Women On Chemotherapy: An Entrepreneur Journey

On this Healthcare Unfiltered episode, I am joined by Kate Dilligan, Founder and CEO of Cooler Heads Care, the manufacturer of a portable scalp cooling system authorized for adults 21 and older undergoing chemotherapy for a solid tumor.

Kate shares her personal journey from being diagnosed with breast cancer to becoming an entrepreneur driven by a mission to help women undergoing chemotherapy mitigate the side effect of hair loss. Kate discusses the science behind the scalp cooling system and its effectiveness in preserving hair. She also delves into her innovative business model that supports infusion centers in remaining profitable, her journey in securing investors, and the future goals of Cooler Heads Care.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More